- Home
- TII vs ALEC Comparison
TII vs ALEC Comparison
Compare TII & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TII | ALEC |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | Canada | United States |
| Employees | 167 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.2M | 228.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | TII | ALEC |
|---|---|---|
| Price | $2.42 | $1.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $6.38 | $4.83 |
| AVG Volume (30 Days) | ★ 1.3M | 869.6K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | $4.20 | $2.03 |
| Revenue Next Year | $3.46 | $29.87 |
| P/E Ratio | $25.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.81 | $1.09 |
| 52 Week High | $5.65 | $3.40 |
Technical Indicators
Market Signals| Indicator | TII | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 53.34 |
| Support Level | $1.99 | $1.93 |
| Resistance Level | $2.44 | $2.05 |
| Average True Range (ATR) | 0.28 | 0.16 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 55.55 | 74.83 |
Price Performance
Historical ComparisonAbout TII Titan Mining Corporation
Titan Mining Corp is a Canadian natural resources company. The company is engaged in the acquisition, exploration, development, and extraction of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States, and Kilbourne Graphite Project. The Company operates one reportable segment, mineral production and exploration in the United States.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.